Table 1

Characteristics of two cases of breakthrough SARS-CoV-2 infections 14+days after the third dose of mRNA vaccine

Case 1Case 2
Type of SARS-CoV-2 vaccinemRNA-1273 (Moderna)BNT162b2 (Pfizer-BioNTech)
Date of mRNA vaccine #129 January 202121 January 2021
Date of mRNA vaccine #226 February 202111 February 2021
Date of mRNA vaccine #322 August 2021 (T)25 August 2021 (T)
Date of breakthrough testing and type23 September 2021
Antigen test (Lumiradx)
10 September 2021
Time from third mRNA dose to SARS-CoV-2 positive testT+32 daysT+16 days
Days from symptom onset to SARS-CoV-2 positive test1 day2 days
Age at breakthrough infection31 years51 years
Type of SARDJuvenile idiopathic arthritis/seronegative inflammatory arthritisSeropositive rheumatoid arthritis
SARD duration23 years14 years
Immunosuppressive medicationsAdalimumab 40 mg SC every other weekCertolizumab pegol 200 mg SC every other week
Smoking statusNever smokerNever smoker
ComorbiditiesNoneHypertension, hyperlipidaemia, obesity, obstructive sleep apnoea
Body mass index (kg/m2)24.135.6
Symptoms of COVID-19Rhinorrhoea, sore throat, dry cough, fever, fatigue, headache, diarrhoea, dysgeusia, anosmiaFever, sore throat, dry cough, chest pain
Treatment of COVID-19Monoclonal antibody (casirivimab/imdevimab) on T+34 daysSupportive care
COVID-19 severity and courseNot hospitalised/fully recoveredNot hospitalised/fully recovered
  • mRNA, messenger ribonucleic acid; SARD, systemic autoimmune rheumatic disease; SC, subcutaneous.